Actieve functies van Karl Richard Gibson
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Ixchelsis Ltd.
 Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | 27-07-2011 | - |
| Oprichter | 27-07-2011 | - | |
| Sandexis LLP | Oprichter | - | - |
Loopbaan van Karl Richard Gibson
Opleiding van Karl Richard Gibson
| University of Cambridge | Doctorate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 4 |
Operationeel
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Consumer Services | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
| Sandexis LLP |
- Beurs
- Insiders
- Karl Richard Gibson
- Ervaring
